, Tracking Stock Market Picks
Enter Symbol:
Xoma Ltd. (XOMA) [hlAlert]

Neutral XOMA
down 86.43 %

Xoma Ltd. (XOMA) downgraded to Neutral by Ladenburg Thalmann

Posted on: Wednesday,  Jul 22, 2015  4:25 PM ET by Ladenburg Thalmann

Ladenburg Thalmann rated Neutral Xoma Ltd. (NASDAQ: XOMA) on 07/22/2015. Previously Ladenburg Thalmann rated Buy Xoma Ltd. (NASDAQ: XOMA) on 03/05/2014.,
when the stock price was $6.93. Since then, Xoma Ltd. has lost 86.44% as of 07/22/2015's recent price of $0.94.
If you would have followed the previous Ladenburg Thalmann's recommendation on XOMA, you would have lost 86.43% of your investment in 504 days.

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA, a monoclonal antibody product marketed worldwide to treat moderate-to-severe plaque psoriasis, and LUCENTIS, a monoclonal antibody product marketed worldwide to treat neovascular age-related macular degeneration. The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage display libraries and XOMA's proprietary Human Engineering and bacterial cell expression technologies. More than forty five companies have signed BCE licenses. XOMA's development collaborators include Lexicon Genetics, Inc., Novartis, and Schering-Plough Corporation. With a fully integrated product development infrastructure, XOMA's product development capabilities extend from preclinical sciences to product launch.

Our Research Department takes a fresh, critical approach to analyzing primary sources and developing proprietary research. Many individuals, institutions, portfolio managers and hedge fund managers, on all levels, have been neglected by brokerage firms ignoring the demands for unbiased research. Ladenburg Thalmann provides a superior branded in-depth research product geared only to action-oriented investment ideas. Ladenburg Thalmann’s proprietary equity research tries to uncover crucial information before the rest of the Street. Our analysts concentrate on uncovered and under-covered stocks and have a small to mid-cap focus. We will not shy away from large cap names as long as we can bring value to our clients through timely, differentiated ideas.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/22/2015 4:25 PM Hold
as of 8/27/2015
1 Week   
1 Month   
3 Months down  -72.59 %
1 YTD down  -86.03 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/5/2014 12:25 PM Buy
6.93 10.00
5/9/2013 2:25 PM Buy
3.98 6.00
1/6/2011 8:25 AM Buy
6.93 16.00
11/11/2008 9:25 AM Buy
17.40 30.00
5/12/2008 2:25 PM Buy
32.25 56.25

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy